Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection

Publisher： Karger

E-ISSN： 1423-0232|73|5-6|324-327

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.5-6, 2008-05, pp. : 324-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 134-142

Karger

Access to resources Recommend Favorite

Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-10 ,pp. : 505-511

Karger

Access to resources Recommend Favorite

Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 157-161

Karger

Access to resources Recommend Favorite

Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 1, 2007-01 ,pp. : 43-48

Bentham Science Publishers

Access to resources Recommend Favorite